OBJECTIVE: The -5T/C polymorphism in the Kozak sequence of glycoprotein Ibalpha, a component of the platelet glycoprotein Ib-IX-V receptor complex, is associated with an increase in this receptor density on the surface of the platelet. This study was designed to investigate the effect of platelet glycoprotein Ibalpha Kozak polymorphism on the clinical presentation of the patients with acute pulmonary embolism. METHODS: Forty-two patients with pulmonary embolism were genotyped for Kozak polymorphism of the glycoprotein Ibalpha by polymerase chain reaction/restriction fragment length polymorphism. RESULTS: Carriers of the -5T/C polymorphism of glycoprotein Ibalpha were significantly over-represented in the patient group with clinically massive or submassive pulmonary embolism (odds ratio 5.5, 95% confidence interval 1.4 to 22.2, P = 0.023). Also the association between this polymorphism and massive or submassive pulmonary embolism still existed even after being adjusted for conventional risk factors. CONCLUSION: The -5T/C polymorphism in the Kozak sequence of glycoprotein Ibalpha may present as a risk factor for clinical manifestation of pulmonary embolism in which clot burden plays an important role.
OBJECTIVE: The -5T/C polymorphism in the Kozak sequence of glycoprotein Ibalpha, a component of the platelet glycoprotein Ib-IX-V receptor complex, is associated with an increase in this receptor density on the surface of the platelet. This study was designed to investigate the effect of platelet glycoprotein Ibalpha Kozak polymorphism on the clinical presentation of the patients with acute pulmonary embolism. METHODS: Forty-two patients with pulmonary embolism were genotyped for Kozak polymorphism of the glycoprotein Ibalpha by polymerase chain reaction/restriction fragment length polymorphism. RESULTS: Carriers of the -5T/C polymorphism of glycoprotein Ibalpha were significantly over-represented in the patient group with clinically massive or submassive pulmonary embolism (odds ratio 5.5, 95% confidence interval 1.4 to 22.2, P = 0.023). Also the association between this polymorphism and massive or submassive pulmonary embolism still existed even after being adjusted for conventional risk factors. CONCLUSION: The -5T/C polymorphism in the Kozak sequence of glycoprotein Ibalpha may present as a risk factor for clinical manifestation of pulmonary embolism in which clot burden plays an important role.
Authors: R I Baker; J Eikelboom; E Lofthouse; N Staples; V Afshar-Kharghan; J A López; Y Shen; M C Berndt; G Hankey Journal: Blood Date: 2001-07-01 Impact factor: 22.113
Authors: H Kimura; O Okada; N Tanabe; Y Tanaka; M Terai; Y Takiguchi; M Masuda; N Nakajima; K Hiroshima; H Inadera; K Matsushima; T Kuriyama Journal: Am J Respir Crit Care Med Date: 2001-07-15 Impact factor: 21.405
Authors: C Meisel; V Afshar-Kharghan; I Cascorbi; M Laule; V Stangl; S B Felix; G Baumann; J A López; I Roots; K Stangl Journal: J Am Coll Cardiol Date: 2001-10 Impact factor: 24.094
Authors: R Gonzalez-Conejero; M L Lozano; J Rivera; J Corral; J A Iniesta; J M Moraleda; V Vicente Journal: Blood Date: 1998-10-15 Impact factor: 22.113